Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Hodson, Elisabeth M ^a   Craig, J C ^b   Strippoli, G F M ^b   Webster, A C ^b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b NONE

Author keywords

*Organ transplantation; Acyclovir analogs derivatives; therapeutic use ; Antiviral agents adverse effects; *therapeutic use ; Cytomegalovirus infections *prevention control ; Ganciclovir therapeutic use

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; PLACEBO; VALACICLOVIR; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANEMIA; BACTERIAL INFECTION; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EMBASE; GRAFT FAILURE; GRAFT RECIPIENT; HALLUCINATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION RISK; KIDNEY DYSFUNCTION; LEUKOPENIA; MEDLINE; MORTALITY; MYCOSIS; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; ORGAN TRANSPLANTATION; PROPHYLAXIS; PROTOZOAL INFECTION; RANDOMIZATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREMOR;

EID: 44949253144     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003774.pub3     Document Type: Review

References (122)

1. Ahsan 97-Kidney {published data only} Ahsan N, Holman MJ, Dhilon S, Ream L, Yang HC. Oral ganciclovir (CytoveneR) effectively prevents cytomegalovirus (CMV) infection in renal transplant patients. [abstract]. Journal of the American Society of Nephrology 1996;7(9):1929.
2. Ahsan N, Holman MJ, Yang HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clinical Transplantation 1997;11(6):633-9. [MEDLINE: 9408699].
3. Badley 97-Liver {published data only} Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, et al.Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. Transplantation 1997;64(1):66-73. [MEDLINE: 9233703].
4. Balfour 89 - Kidney {published data only} Balfour HH, Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. New England Journal of Medicine 1989;320(21):1381-7. [MEDLINE: 2541335].
5. Barkholt 99 - Liver {published data only} Barkholt L, Lewensohn-Fuchs I, Ericzon BG, Tyden G, Andersson J. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transplant Infectious Disease 1999;1(2):89-97. [MEDLINE: 11428976].
6. Brennan 97-Kidney {published data only} Brennan DC, Garlock KA, Singer GG, Schnitzler MA, Lippmann BJ, Buller RS, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997;64(12):1843-6. [MEDLINE: 9422429].
7. Cohen 93-Liver {published data only} Cohen AT, O'Grady JG, Sutherland S, Sallie R, Tan K-C, Williams R. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. Journal of Medical Virology 1993;40(1):5-9. [MEDLINE: 8390559].
8. Conti 95-Kidney {published data only} Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N, et al.Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Archives of Surgery 1995;130(11):1217-22. [MEDLINE: 7487465].
9. Duncan 93-Lung {published data only} Duncan SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL, et al.A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. American Journal of Respiratory & Critical Care Medicine 1994;150(1):146-52. [MEDLINE: 8025741].
10. Egan 02-Heart {published data only} Egan JJ, Carroll KB, Yonan N, Woodcock A, Crisp A. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. Journal of Heart & Lung Transplantation 2002;21(4):460-6. [MEDLINE: 11927223].
11. Flechner 98-Kidney {published data only} Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, et al.A randomized prospective controlled trial of oral acyclovir versus oral, ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998;66(12):1682-8. [MEDLINE: 9884259].
12. Gane 97-Liver {published data only} Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al.Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997;350(9093):1729-33. [MEDLINE: 9413463].
13. Saliba F, Bismuth H, Gane E, Valdecasas G, O'grady J, Behrend M, et al.A randomized double blind versus placebo multicenter study of efficacy and tolerance of oral ganciclovir in the prevention of cytomegalovirus disease in hepatic transplanted patients. Gastroenterologie Clinique et Biologique 1997;21(2 bis):A157.
14. Gavalda 97-Liver {published data only} Gavalda J, De Otero J, Murio E, Vargas V, Rossello J, Calico I, et al.Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transplant International 1997;10(6):462-5. [MEDLINE: 9428121].
15. Green 97-Liver {published data only} Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clinical Infectious Diseases 1997;25(6):1344-9. [MEDLINE: 9431375].
16. Hertz 98-heart/lung {published data only} Hertz MI, Jordan C, Savik SK, Fox JMK, Park S, Bolman II RM, et al.Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. Journal of Heart & Lung Transplantation 1998;17(9):913-20. [MEDLINE: 9773865].
17. Hibberd 95-Kidney {published data only} Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al.Preemptive ganciclovir therapy to prevent cytomegalovirus disease, in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Annals of Internal Medicine 1995;123(1):18-26. [MEDLINE: 7762909].
18. Kletzmayr 96-Kidney {published data only} Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. Journal of the American Society of Nephrology 1996;7(2):325-30. [MEDLINE: 8785404].
19. Leray 95-Kidney {published data only} Leray H, Mourad G, Chong G, Segondy M, Mion C. Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients. Transplantation Proceedings 1995;27(4):2448. [MEDLINE: 7652875].
20. Lowance 99-Kidney {published data only} Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al.Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. New England Journal of Medicine 1998;340(19):1462-70. [MEDLINE: 10320384].
21. Macdonald 95-Heart {published data only} Macdonald PS, Keogh AM, Marshman D, Richens D, Harvison A, Kaan AM, et al.A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. Journal of Heart & Lung Transplantation 1995;14(1):32-8. [MEDLINE: 7727473].
22. Martin 94-Liver {published data only} Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, et al.A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994;58(7):779-85. [MEDLINE: 7940710].
23. Merigan 92-Heart {published data only} Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, et al.A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. New England Journal of Medicine 1992;326(18):1182-6. [MEDLINE: 1313549].
24. Nafar 05-Kidney {published data only} Nafar M, Pezeshki ML, Farrokhi F, Einollahi B, Pour-Reza-Gholi F, Firouzan A, et al.A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Transplantation Proceedings 2005;37(7):3053-5. [MEDLINE: 16213302].
25. Nakazato 93-Liver {published data only} Nakazato PZ, Burns W, Moore P, Garcia-Kennedy R, Cox K, Esquivel C. Viral prophylaxis in hepatic transplantation: Preliminary report of a randomized trial of acyclovir and gancyclovir. Transplantation Proceedings 1993;25(2):1935-7. [MEDLINE: 7682357].
26. Pavlopoulou 05-K {published data only} Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, et al.A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clinical Microbiology & Infection 2005;11(9):736-43. [MEDLINE: 16104989].
27. Paya 04-All {published data only} Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al.Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. American Journal of Transplantation 2004;4(4):611-20. [MEDLINE: 15023154].
28. Pouteil-Noble 96 - K {published data only} Pouteil-Noble C, Megas F, Chapuis F, Bosshard S, Colin C, Hadj-Aissa A, et al.Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: A randomized, controlled trial. Transplantation Proceedings 1996;28(5):2811. [MEDLINE: 8908072].
29. Reischig 05 - Kidney {published and unpublished data} *Reischig T, Jindra P, Mares J, Opatrny K, Cechura M, Svecova M, et al.Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005;79(3):317-24. [MEDLINE: 15699762].
30. Reischig T, Jindra P, Mares J, Opatrny K, Jr, Treska V, Cechura M, et al.Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection: a randomized comparison of oral ganciclovir and valacyclovir [abstract 1225]. American Journal of Transplantation 2004;4(Suppl 8):493.
31. Reischig T, Opatrny K, Jr, Bouda M, Treska V, Jindra P, Svecova MT, et al.A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transplant International 2002;15(12):615-22. [MEDLINE: 12478408].
32. Rondeau 93-Kidney {published data only} Rondeau E, Bourgeon B, Peraldi MN, Lang P, Buisson C, Schulte KM, et al.Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrology Dialysis Transplantation 1993;8(9):858-62. [MEDLINE: 8255520].
33. Rostaing 94 - Kidney {published data only} Rostaing L, Crespin A, Icart J, Lloveras JJ, Durand D, Martinet O, et al.Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients. Transplant International 1994;7 Suppl 1:331-5. [MEDLINE: 11271244].
34. Rubin 02-all {published data only} Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, et al.Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transplant Infectious Disease 2000;2(3):112-7. [MEDLINE: 11429021].
35. Saliba 93-Liver {published data only} Saliba F, Eyraud D, Samuel D, David MF, Arulnaden JL, Dussaix E, et al.Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplantation Proceedings 1993;25(1 Pt 2):1444-5. [MEDLINE: 8382876].
36. Winston 03-Liver {published data only} Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003;75(2):229-33. [MEDLINE: 12548129].
37. Winston 04-Liver {published data only} Winston DJ, Busuttil RW. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004;77(2):305-8. [MEDLINE: 14742998].
38. Winston 95-Liver {published data only} Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346(8967):69-74. [MEDLINE: 7603215].
39. Ahsan 1998 Ahsan N, Holman MJ, Sonderbye L, Langhoff E, Yang HC. Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant 'CMV at risk' recipients: A controlled, comparative study of two regimens (750mg Bid and 500mg Bid). Transplantation Proceedings 1998;30(4):1383-5. [MEDLINE: 9636560].
40. Arbo 2000 Arbo MD, Snydman DR, Wong JB, Goldberg HS, Schmid CH, Pauker SG. Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis. Clinical Transplantation 2000;14(1):19-27. [MEDLINE: 10693631].
41. Brennan 1997 Brennan DC, Garlock KA, Lippmann BA, Buller RS, Gaudreault-Keener M, Lowell JA, et al.Control of cytomegalovirus-associated morbidity in renal transplant patients using intensivemonitoring and either preemptive or deferred therapy. Journal of the American Society of Nephrology 1997;8(1):118-25. [MEDLINE: 9013456].
42. Brennan 2001 Brennan DC. Cytomegalovirus in renal transplantation. Journal of the American Society of Nephrology 2001;12(4):848-55. [MEDLINE: 11274248].
43. Couchoud 1998a Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998;65(5):641- 7. [MEDLINE: 9521197].
44. Dickinson 1996 Dickinson BI, Gora-Harper ML, McCraney SA, Gosland M. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Annals of Pharmacotherapy 1996;30(12):1452-64. [MEDLINE: 8968459].
45. Falagas 1997 Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, et al.Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clinical Transplantation 1997;11(5 Pt 1):432-7. [MEDLINE: 9361936].
46. Fehir 1989 Fehir KM, Decker WA, Samo T, Young JB, Lederer E, Lawrence EC. Immune globulin (GAMMAGARD)prophylaxis of CMVinfections in patients undergoing organ transplantation and allogeneic bone marrow transplantation. Transplantation Proceedings 1989;21(1 Pt 3):3107-9. [MEDLINE: 2539691].
47. Fishman 2000 Fishman JA, Doran MT, Volpicelli SA, Cosimi AB, Flood JG, Rubin RH. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2000;69(3):389-94. [MEDLINE: 10706048].
48. Gerna 2003 Gerna G, Baldanti F, Lilleri D, Parea M, Torsellini M, Castiglioni B, et al.Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation 2003;75(7):1012-9. [MEDLINE: 12698090].
49. Glowacki 1994 Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a metaanalysis. Clinical Transplantation 1994;8(1):10-8. [MEDLINE: 8136560].
50. Griffiths 1997 Griffiths PD. Prophylaxis against CMV infection in transplant patients. Journal of Antimicrobial Chemotherapy 1997;39(3):299-301. [MEDLINE: 9096177].
51. Huurman 2006 Huurman VA, Kalpoe JS, van de LP, Vaessen N, Ringers J, Kroes AC, et al.Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006;29(4):842-7. [MEDLINE: 16567825].
52. Jung 2001 Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplantation Proceedings 2001;33(8):3621-3. [MEDLINE: 11750538].
53. Jurim 1996 Jurim O, Martin P, Winston DJ, Shackleton C, Holt C, Feller J, et al.Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection. Liver Transplantation & Surgery 1996;2(5):370-4. [MEDLINE: 9346678].
54. Khoury 2006 Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al.Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. American Journal of Transplantation 2006;6(9):2134-43. [MEDLINE: 16780548].
55. Kim 2000 Kim WR, Badley AD, Wiesner RH, Porayko MK, Seaberg EC, Keating MR, et al.The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 2000;69(3):357-61. [MEDLINE: 10706042].
56. King 1999 King SM. Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients. Antiviral Research 1999;40(3):115-37. [MEDLINE: 10027647].
57. Kletzmayr 2000 Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000;70(8):1174-80. [MEDLINE: 11063336].
58. Koetz 2001 Koetz AC, Delbruch R, Furtwangler A, Hufert FT, Neumann-Haefelin D, Kirste G, et al.Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective double-blind, placebo-controlled study. Transplantation 2001;72(7):1325-7. [MEDLINE: 11602864].
59. Kuypers 1999 Kuypers DR, Vanrenterghem YF. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem. Nephrology Dialysis Transplantation 1999;14(10):2304-8. [MEDLINE: 10528649].
60. Laske 1991 Laske A, Gallino A, Mohacsi P, Bauer EP, Carrel T, Von Segesser LK, et al.Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation. Transplantation Proceedings 1991;23(1 Pt 2):1170-3. [MEDLINE: 1846456].
61. Laske 1992 Laske A, Carrel T, Niederhauser U, Bauer E, Pasic M, Von Segesser LK, et al.The prevention of cytomegalus infection after heart transplantation. Helvetica Chirurgica Acta 1992;58(4):527-32.
62. Lumbreras 1993 Lumbreras C, Otero JR, Herrero JA, Gomez R, Lizasoain M, Aguado JM, et al.Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrobial Agents & Chemotherapy 1993;37(11):2490-2. [MEDLINE: 8285641].
63. Martin 1993 Martin M. Antiviral prophylaxis for CMV infection in liver transplantation. Transplantation Proceedings 1993;25(5 Suppl 4):10-4. [MEDLINE: 8212301].
64. Martin 1994 Martin M. Combination antiviral strategies in managing cytomegalovirus infection. Transplantation Proceedings 1994;26(5 Suppl 1):28-30. [MEDLINE: 7940973].
65. Martin 1995 Martin M. Prophylactic cytomegalovirus management strategies. Transplantation Proceedings 1995;27(5 Suppl 1):23-7. [MEDLINE: 7482812].
66. McGavin 2001 McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001;61(8):1153-83. [MEDLINE: 11465876].
67. Moreno 1999 Moreno J, Montero JL, Gavilan F, Costan G, Herrero C, Cardenas M, et al.Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients. Enfermedades Infecciosas y Microbiologia Clinica 1999;17(8):382-5. [MEDLINE: 10563084].
68. Mullen 1998 Mullen GM, Silver MA, Malinowska K, Lawless CE, Lichtenberg RC, Barath PC, et al.Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients. Transplantation Proceedings 1998;30(8):4110-2. [MEDLINE: 9865316].
69. Paya 2002 Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, et al.Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. Journal of Infectious Diseases 2002;185(7):854-60. [MEDLINE: 11920308].
70. Queiroga 2003 Quieroga M, Castro MC, Araujo LM, Alves CF, Kakehashi E, Panutti C, et al.A prospective, randomized controlled trial comparing oral ganciclovir with weekly monitored CMV-antigenemia in renal transplant patients with a high-risk for CMV infection [abstract]. American Journal of Transplantation 2003;3(Suppl 5):511.
71. Rayes 2001 Rayes N, Seehofer D, Schmidt CA, Oettle H, Muller AR, Steinmuller T, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001;72(5):881-5. [MEDLINE: 11571454].
72. Reischig 2006 Reischig T, Jindra P, Svecova M, Kormunda S, Opatrny K, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. Journal of Clinical Virology 2006;36(2):146-51. [MEDLINE: 16531113].
73. Sagedal 2003 Sagedal S, Nordal KP, Hartmann A, Midvedt K, Foss A, Asberg A, et al.Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrology Dialysis Transplantation 2003;18(9):1899-908. [MEDLINE: 12937241].
74. Schafers 1988 Schafers H-J, Wahlers T, Jurmann M, Fieguth H-G, Milbradt H, Flik J, et al.Hyperimmuneglobulin for cytomegalovirus prophylaxis following heart transplantation. Journal of Hospital Infection 1988;Vol 12(Suppl D):61-5. [MEDLINE: 2902131].
75. Schnitzler 2000 Schnitzler MA, Metheney TG, Rueda JF, Woodward RS, Lowell JA, Singer GG, et al.A 3-year follow-up of pre-emptive vs deferred treatment of cytomegalovirus disease in renal transplantation. Clinical Drug Investigation 2000;19(5):367-74.
76. Singh 1994 Sing N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowsky T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Annals of Internal Medicine 1994;120(5):375-81. [MEDLINE: 8304654].
77. Singh 1995 Singh TP, Gruber SA, Lempert N, Freed B, Conti DJ. Efficacy of cytomegalovirus prophylaxis in renal retransplantation. Transplantation Proceedings 1995;27(1):964-5. [MEDLINE: 7879247].
78. Singh 2000 Sing N, Paterson DL, Gayowsky T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus iv ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. Transplantation 2000;70(5):717-22. [MEDLINE: 11003347].
79. Snydman 1991a Snydman DR. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with intravenous immune globulin. Transplantation Proceedings 1991;23(2 Suppl 1):20-5. [MEDLINE: 1647560].
80. Snydman 1991b Snydman DR, Werner BG, Tilney NL, Kirkman RL, Milford EL, Cho SI, et al.Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplantation Proceedings 1991;23(1 Pt 2):1357-60. [MEDLINE: 1846464].
81. Snydman 1994 Snydman DR, Werner BG, Dougherty NN, Griffith J, Rohrer RH, Freeman R, et al.A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG Study Group. Transplantation Proceedings 1994;26(5 Suppl 1):23-7. [MEDLINE: 7940972].
82. Snydman 2001a Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transplant Infectious Disease 2001;3(Suppl 2):6-13. [MEDLINE: 11926753].
83. Speich 1999 Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999;67(2):315-20. [MEDLINE: 10075601].
84. Stratta 1992 Stratta RJ, Shaefer MS, Cushing KA, Markin RS, Reed EC, Langnas AN, et al.A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3therapy. Archives of Surgery 1992;127(1):55-64. [MEDLINE: 1310385].
85. Turgeon 1998 Turgeon N, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, et al.Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998;66(12):1780- 6. [MEDLINE: 9884276].
86. Valantine 1995 Valantine HA. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: Evidence for a beneficial effect of hyperimmune globulin. Transplantation Proceedings 1995;27(5 Suppl 1):49-57. [MEDLINE: 7482821].
87. Valantine 1999 Valantine HA, Gao S-Z, Menon SG, Renlund DG, Hunt SA, Oyer P, et al.Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation 1999;100(1):61-6. [MEDLINE: 10393682].
88. Wittes 1996 Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplantation Proceedings 1996;28(6 Suppl 2):17-24. [MEDLINE: 9037273].
89. Yang 1998 Yang CW, Kim YO, Kin YS, Kin SY, Moon IS, Ahn HJ, et al.Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. American Journal of Nephrology 1998;18(5):373-8. [MEDLINE: 9730559].
90. Yang 1999 Yang HC, Holman MJ, Langhoff E, Dellock CA, Gupta M, Ulsh PJ, et al.A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant 'CMV at risk' recipients. Transplantation Proceedings 1999;31(1-2):1125-6. [MEDLINE: 10083502].
91. Baliga 2004 Baliga RS, Kadambi PV, Javaid B, Harland R, Williams JW, Thistlethwaite JR, et al.A nationwide survey of cytomegalovirus prophylaxis and treatment in the transplant community [abstract]. American Journal of Transplantation 2004;4(Suppl 8):495.
92. Basgoz 1995 Basgoz N, Preiksaitis J. Post-transplant lymphoproliferative disorder. Infectious Diseases Clinics of North America 1995;9(4):901-23. [MEDLINE: 8747772].
93. Couchoud 1998b Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database of Systematic Reviews 1998, Issue 4.Art. No.: CD001320. DOI:10.1002/14651858. CD001320.pub2.
94. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286- 91. [MEDLINE: 7718048].
95. Emery 2000 Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355(9220):2032-6. [MEDLINE: 10885354].
96. Fiddian 2002 Fiddian P, Sabin CA, Griffiths PD. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. Journal of Infectious Diseases 2002;186 Suppl 1:110-5. [MEDLINE: 12353195].
97. Fishman 1995 Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infectious Disease Clinics of North America 1995;9(4):1005-44. [MEDLINE: 8747777].
98. Fishman 1998 Fishman JA, Rubin RH. Infection in organ-transplant recipients. New England Journal of Medicine 1998;338(24):1741-51. [MEDLINE: 9624195].
99. George 1997 George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, et al.The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. American Journal of Medicine 1997;103(2): 106-13. [MEDLINE: 9274893].
100. Gourishankar 2001 Gourishankar S, Wong W, Dorval M. Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to acyclovir?. Transplantation Proceedings. 2001; Vol. 33, issue 1-2:1870-2.
101. Grattan 1989 Grattan MT, Moreno-Cabral CE, Starnes BA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261(24):3561-6. [MEDLINE: 2542633].
102. Hadley 1995 Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infectious Disease Clinics of North America 1995;9(4):1045-74. [MEDLINE: 8747778].
103. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60. [MEDLINE: 12958120].
104. Hodson 2007 Hodson EM, Jones CA, Strippoli GFM, Webster AC, Craig JC. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2007, Issue 2.Art. No.: CD005129. DOI:10.1002/14651858.CD005129. pub2.
105. Hollis 1999 Hollis S, Cambell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [MEDLINE: 10480822].
106. Jassal 1998 Jassal SV, Roscoe JM, Zaltzman JS, Mazzulli T, Krajden M, Gadawski M, et al.Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. Journal of the American Society of Nephrology 1998;9(9):1697-708. [MEDLINE: 9727379].
107. Keenan 1991 Keenan RJ, Lega ME, Dummer JS, Paradis IL, Dauber JH, Rabinowich H, et al.Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991;51(2):433-8. [MEDLINE: 1847251].
108. Lefebvre 1996 Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomised controlled trials in Embase. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia). 1996.
109. Linden 2000 Linden PK. Infections in liver transplant recipients. In: GlauserMP, PizzoPA editor(s). Management of infections in immunocompromised patients. 1st Edition. United Kingdom: WB Saunders, 2000:295-322.
110. Master List 2007 United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed May 2007).
111. Michaels 2000 Michaels M, Green M. Infections in lung and heart-lung transplant recipients. In: GlauserMP, PizzoPA editor(s). Management of infections in immunocompromised patients. 1st Edition. United Kingdom: WB Saunders, 2000:363-93.
112. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported inmeta-analyses?. Lancet 1998;352(9128):609-13. [MEDLINE: 9746022].
113. Rubin 1989 Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989;261(24):3607-9. [MEDLINE: 2542634].
114. Rubin 2000 Rubin RH, Rosenberg E. Infection in solid organ transplant: an introduction. In: GlauserMP, PizzoPA editor(s). Management of infections in immunocompromised patients. 1st Edition. United Kingdom: WB Saunders, 2000:246-65.
115. Schultz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-
116. Strippoli 2006a Strippoli GFM, Hodson EM, Jones CA, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2006, Issue 1.Art. No.: CD005133. DOI:10.1002/14651858.CD005133. pub2.
117. Strippoli 2006b Strippoli GF, Hodson EM, Jones CA, Craig JC. Preemptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006;81(2):139-45. [MEDLINE: 16436954].
118. Valentine 1999 Valantine HA. Role of CMV in transplant coronary artery disease and survival after heart transplantation. Transplant Infectious Disease 1999;1 Suppl 1:25-30. [MEDLINE: 11565583].
119. Van den Berg 1996 Van den Berg AP, Klompmaker IJ, Haagsma EB, Peeters PM, Meerman L, Verwer R, et al.Evidence for increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clinical Transplantation 1996;10(2):224-31. [MEDLINE: 8664524].
120. Van der Bij 2001 Van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clinical Infectious Diseases 2001;33 Suppl 1:32-7. [MEDLINE: 11389520].
121. Hodson 2005a Hodson EM, Jones CA, Webster AC, Strippoli GFM, Barclay BG, Kable K, et al.Antiviral medications to prevent cytomegalovirus disease and early death in solid-organ transplant recipients: a systematic review of randomised controlled trials. Lancet 2005;365(9477): 2105-15. [MEDLINE: 15964447].
122. Hodson 2005b Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GFM, et al.Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2005, Issue 4.Art. No.: CD003774. DOI:10.1002/14651858.CD003774. pub2.